Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020. The document serves as a transaction notification regarding a purchase of company securities by a Principal Director or Manager (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a disclosure of a specific insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Transaction Date | November 9, 2020 |
| Price per ADS | $37.4900 |
| Volume | 1,111.623 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction within an Executive Supplemental Savings Plan account.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was executed by Dr. H. Barron, Chief Scientific Officer and President, R&D.
Investor Verification Points
- Verify the total number of ADSs held by Dr. H. Barron following this acquisition to assess overall insider ownership concentration.
- Confirm the specific terms of the GSK Executive Supplemental Savings Plan to understand the nature of the acquisition (e.g., automatic payroll deduction vs. discretionary purchase).
- Check subsequent filings for any sales or additional purchases by Dr. Barron to identify trading patterns.